Table 2.
Classification of US FDA-approved epigenetic drug classes according to mechanism of action.
| Mechanism of Action | Active Ingredient (Trade name®, Proprietor) | Date of Approval | Indication(s) |
|---|---|---|---|
| DNA N-Methyltransferase Inhibitor (DNMTi) | Azacitidine (Vidaza®, Celgene) | May 19, 2004 | Chronic Myelomonocytic Leukemia. Myelodysplastic Syndrome i. |
| Decitabine(Dacogen®, Otsuka) | May 2, 2006 | Chronic Myelomonocytic Leukemia. Myelodysplastic Syndromes ii. | |
|
| |||
| Histone Deacetylase inhibitors (HDACi) | Vorinostat(Zolinza®, Merck) | October 6, 2006 | Cutaneous manifestations in patients with cutaneous T-Cell Lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies. |
| Romidepsin(Istodax®, Celgene) | November 5,2009 | Cutaneous T-cell Lymphoma (CTCL) iii, Peripheral T-cell Lymphoma (PTCL) iii | |
| Belinostat(Beleodaq®, Spectrum Pharmaceuticals) | July 3, 2014 | Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | |
| Panobinostat(Farydak®, Novartis) | February 23, 2015 | Multiple Myeloma after receiving at least 2 prior regimens, including bortezomib and an immunomodulatory agent iv | |
Subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation.
Including 90 previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes 91 (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, 92 refractory anemia with excess blasts in transformation, and 93 intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups).
In patients who have received at least one prior systemic therapy.
In combination with bortezomib and dexamethasone.